Daré Bioscience walks into tomorrow's earnings print carrying the fastest short-interest build of any comparable window in recent months — a signal that at least some traders are betting the strong May rally has run ahead of the fundamentals.
The most striking data point heading into the May 14 report is the pace of short accumulation. Short interest has risen roughly 350% over the past month and is up more than 130% in the last week alone, climbing to 5.7% of the float. That pace is unusual for a micro-cap pharma trading around $2.63. The ORTEX short score has moved with it, rising from the mid-40s at end-April to 56.7 — a meaningful shift in bearish conviction even if the absolute level remains moderate. Borrow conditions are still accessible at 1.6% cost-to-borrow, and availability has not tightened to alarm levels, suggesting the short build reflects directional positioning rather than a forced squeeze dynamic.
That short accumulation sits awkwardly against DARE's own price performance. The stock is up 44% over the past month — a run that pulled back sharply this week, with a 20% loss over the past five days before a 4% bounce Tuesday. The pattern is consistent with momentum traders cycling in and out of a low-float name. The most recent earnings event on record — the March 2026 print — produced a 10.7% one-day gain and a 24.3% five-day follow-through, suggesting positive results can drive outsized moves in a thinly traded stock. The prior event, in November 2025, went the other way: a 6% one-day drop followed by a 17.7% five-day decline.
Analyst coverage remains thin and dated. HC Wainwright has reiterated its Buy rating and a $12 target multiple times, most recently in December 2025 — well above the current price but too stale to treat as live guidance on the current setup. Maxim Group upgraded to Buy last September with an $8 target. Both targets sit well above today's price, but given the staleness of the data and the volatility of the name, those levels reflect older thesis views rather than current positioning.
The earnings report tomorrow is therefore less about the direction of analyst sentiment and more about whether the company can provide a clinical or financial update substantial enough to justify a stock that has tripled off recent lows — or hand the sharply expanded short base the catalyst it has been building toward.
See the live data behind this article on ORTEX.
Open DARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
